Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Surgery Today
Erschienen in: Surgery Today 9/2019

08.03.2019 | Review Article

The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development

verfasst von: Mayumi Higashi, Kohei Sakai, Shigehisa Fumino, Shigeyoshi Aoi, Taizo Furukawa, Tatsuro Tajiri

Erschienen in: Surgery Today | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Neuroblastoma is one of the most frequent, yet distinctive and challenging childhood tumors. The uniqueness of this tumor depends on its biological markers, which classify neuroblastomas into favorable and unfavorable, with 5-year survival rates ranging from almost 100–30%. In this review, we focus on some biological factors that play major roles in neuroblastoma: MYCN, Trk, and ALK. The MYCN and Trk family genes have been studied for decades and are known to be crucial for the tumorigenesis and progression of neuroblastoma. ALK gene mutations have been recognized recently to be responsible for familial neuroblastomas. Each factor plays an important role in normal neural development, regulating cell proliferation or differentiation by activating several signaling pathways, and interacting with each other. These factors have been studied not only as prognostic factors, but also as targets of neuroblastoma therapy, and some clinical trials are ongoing. We review the basic aspects of MYCN, Trk, and ALK in both neural development and in neuroblastoma.
Literatur
1.
2.
Domingo-Fernandez R, Watters K, Piskareva O, Stallings RL, Bray I. The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatr Surg Int. 2013;29:101–19.CrossRefPubMed
3.
Decock A, Ongenaert M, De Wilde B, Brichard B, Noguera R, Speleman F, et al. Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait. Epigenetics. 2016;11:761–71.CrossRefPubMedPubMedCentral
4.
Olsson M, Beck S, Kogner P, Martinsson T, Carén H. Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors. Epigenetics. 2016;11:74–84.CrossRefPubMedPubMedCentral
5.
Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–5.CrossRefPubMedPubMedCentral
6.
Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455:967–70.CrossRefPubMed
7.
Mossé YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res. 2009;15:5609–14.CrossRefPubMed
8.
Barone G, Anderson J, Pearson ADJ, Petrie K, Chesler L. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clin. Cancer Res. 2013;19:5814–21.
9.
Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell. 1983;35:359–67.CrossRefPubMed
10.
Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop J. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 1984;81:4940–4.CrossRef
11.
Wakamatsu Y, Watanabe Y, Nakamura H, Kondoh H. Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation. Development. 1997;124:1953–62.PubMed
12.
Brodeur GM, Seeger RC, Schwab M, Varmus H, Bishop J. Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage. Prog Clin Biol Res. 1985;175:105–13.PubMed
13.
Mathew P, Valentine MB, Bowman LC, Rowe ST, Nash MB, Valentine V, et al. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia. 2001;3:105–9.CrossRefPubMedPubMedCentral
14.
Storlazzi CT, Lonoce A, Guastadisegni MC, Trombetta D, Addabbo PD, Daniele G, et al. Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res. 2010;20:1198–206.CrossRefPubMedPubMedCentral
15.
Reiter JL, Brodeur GM. High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas. Genomics. 1996;32:97–103.CrossRefPubMed
16.
Reiter JL, Brodeur GM. MYCN is the only highly expressed gene from the core amplified domain in human neuroblastomas. Genes Chromosom Cancer. 1998;23:134–40.CrossRefPubMed
17.
Nishi Y, Noguchi T, Akiyama K, Yokoyama M, Kanda NMT. Amplification of a DEAD box gene (DDX1) with the MYCN gene in neuroblastoma as a result of cosegregation of sequences flanking the MYCN locus. Genes Chromosom. Cancer. 1996;15:129–33.
18.
Kaneko S, Ohira M, Nakamura Y, Isogai E, Nakagawara A, Kaneko M. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. J Cancer Res Clin Oncol. 2007;133:185–92.CrossRefPubMed
19.
Bagci O, Tumer S, Olgun N, Altungoz O. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors. Cancer Lett. 2012;317:72–7.CrossRefPubMed
20.
Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, et al. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors. Genes Chromosom Cancer. 2015;54:99–109.CrossRefPubMed
21.
Wada RK, Seeger RC, Brodeur GM, Einhorn PA, Rayner SA, Tomayko MM, et al. Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer. 1993;72:3346–54.CrossRefPubMed
22.
Nakada K, Fujioka T, Kitagawa H, Takakuwa T. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis. Jpn J Clin Oncol. 1993;23:149–55.PubMed
23.
Tanaka T, Higashi M, Kimura K, Wakao J, Fumino S, Iehara T. MEK inhibitors as a novel therapy for neuroblastoma: their in vitro effects and predicting their efficacy. J Pediatr Surg. 2016;51:2074–9.CrossRefPubMed
24.
Wenzel A, Cziepluch C, Hamann U, Schürmann J, Schwab M. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. EMBO J. 1991;10:3703–12.CrossRefPubMedPubMedCentral
25.
Wanzel M, Herold S, Eilers M. Transcriptional repression by Myc. Trends Cell Biol. 2003;13:146–50.CrossRefPubMed
26.
Brenner C, Deplus R, Line Didelot C, Loriot A, Viré E, De Smet C, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 2005;24:336–46.CrossRefPubMed
27.
Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 2015;511:483–7.CrossRef
28.
Corvetta D, Chayka O, Gherardi S, D’Acunto CW, Cantilena S, Valli E, et al. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: Functional and therapeutic implications. J Biol Chem. 2013;288:8332–41.CrossRefPubMedPubMedCentral
29.
30.
Kubota Y, Kim S, Iguchi-Ariga S. H A. Transrepression of the N-myc expression by c-myc protein. Biochem Biophys Res Commun. 1989;162:991–7.CrossRefPubMed
31.
Cotterman R, Knoepfler PS. N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b. PLoS One. 2009;4.
32.
Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, Moreno De Alborán I, Olson JM, et al. N-myc is an essential downstream effector of shh signaling during both normal and neoplastic cerebellar growth. Cancer Res. 2006;66:8655–61.CrossRefPubMed
33.
Smith JR, Moreno L, Heaton SP, Chesler L, Pearson ADJ, Garrett MD. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Mol Oncol. 2016;10:538–52.CrossRefPubMed
34.
Segerström L, Baryawno N, Sveinbjörnsson B, Wickström M, Elfman L, Kogner P, et al. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer. 2011;129:2958–65.CrossRefPubMed
35.
Kapeli K, Hurlin PJ. Differential regulation of N-Myc and c-Myc synthesis, degradation, and transcriptional activity by the ras/mitogen-activated protein kinase pathway. J Biol Chem. 2011;286:38498–508.CrossRefPubMedPubMedCentral
36.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997;16:2985–95.CrossRefPubMedPubMedCentral
37.
Hansford LM, Thomas WD, Keating JM, Burkhart C, Peaston AE, Norris MD, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci USA. 2004;101:12664–9.CrossRef
38.
Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3:309–23.CrossRef
39.
Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, et al. Targeting MYCN-driven transcription by BET-bromodomain inhibition. Clin Cancer Res. 2016;22:2470–81.CrossRefPubMed
40.
Benedetti M, Levi A, Chao MV. Differential expression of nerve growth factor receptors leads to altered binding affinity and neurotrophin responsiveness. Proc Natl Acad Sci USA. 1993;90:7859–63.
41.
42.
Anderson D. Cell fate determination in the peripheral nervous system: the sympathoadrenal progenitor. J Neurobiol. 1993;24:185–98.CrossRefPubMed
43.
Patapoutian A, Reichardt LF. Trk receptors: Mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11:272–80.CrossRefPubMed
44.
Lu Y, Christian K, Lu B. BDNF: A key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem. 2008;89:312–23.CrossRefPubMed
45.
Li Z, Zhang Y, Tong Y, Tong J, Thiele CJ. Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo. Cancer Biol Ther. 2015;16:477–83.CrossRefPubMedPubMedCentral
46.
Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood. 2005;105:4429–36.CrossRefPubMed
47.
Haapasalo A, Saarelainen T, Moshnyakov M, Aruma U, Kiema T, Saarma M, et al. Expression of the naturally occurring truncated trkB neurotrophin receptor induces outgrowth of filopodia and processes in neuroblastoma cells. Oncogene. 1999;18:1285–96.CrossRefPubMed
48.
Stoilov P, Castren E, Stamm S. Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem Biophys Res Commun. 2002;290:1054–65.CrossRefPubMed
49.
Tacconelli A, Farina AR, Cappabianca L, DeSantis G, Tessitore A, Vetuschi A, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell. 2004;6:347–60.CrossRefPubMed
50.
Hoehner JC, Olsen L, Sandstedt B, Kaplan DR, Påhlman S. Association of neurotrophin receptor expression and differentiation in human neuroblastoma. Am J Pathol. 1995;147:102–13.PubMedPubMedCentral
51.
Yamashiro D, Nakagawara A, Ikegaki N, Liu X, Brodeur G. Expression of TrkC in favorable human neuroblastoma. Oncogene. 1996;12:37–41.PubMed
52.
Ho R, Minturn JE, Simpson AM, Iyer R, Light JE, Evans AE, et al. The effect of P75 on Trk receptors in neuroblastomas. Cancer Lett. 2011;305:76–85.CrossRefPubMedPubMedCentral
53.
Nikoletopoulou V, Lickert H, Frade JM, Rencurel C, Giallonardo P, Zhang L, et al. Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature. 2010;467:59–63.CrossRefPubMed
54.
Nakagawara A. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993;328:847–53.CrossRefPubMed
55.
56.
Norris RE, Minturn JE, Brodeur GM, Maris JM, Adamson PC. Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. Cancer Chemother Pharmacol. 2011;68:1469–75.CrossRefPubMedPubMedCentral
57.
Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011;68:1057–65.CrossRefPubMedPubMedCentral
58.
Leitão A, Schramm A, Eggert A. Discovery of a new bioactive molecule for neuroblastoma. Chem Biol Drug Des. 2013;82:233–41.CrossRefPubMed
59.
Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, et al. The ALKF1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012;22:117–30.CrossRefPubMedPubMedCentral
60.
Montavon G, Jauquier N, Coulon A, Peuchmaur M, Flahaut M, Bourloud KB, et al. Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells. Oncotarget. 2014;5:4452–66.CrossRefPubMedPubMedCentral
61.
Pulford K, Lamant L, Espinos E, Jiang Q, Xue L, Turturro F, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004;61:2939–53.CrossRefPubMed
62.
Allouche M. ALK is a novel dependence receptor: potential implications in development and cancer. Cell Cycle. 2007;6:1533–8.CrossRefPubMed
63.
Umapathy G, Wakil A, El Witek B, Chesler L, Danielson L, Deng X, et al. The kinase ALK stimulates the kinase ELK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014;7:1–11.CrossRef
64.
Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, et al. Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: implications for targeted treatment. Clin Cancer Res. 2015;21:3327–39.CrossRefPubMed
65.
Cazes A, Lopez-Delisle L, Tsarovina K, Pierre-Eugène C, De Preter K, Peuchmaur M, et al. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. Oncotarget. 2014;5:2688–702.CrossRefPubMedPubMedCentral
66.
Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472–80.CrossRefPubMedPubMedCentral
67.
Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, et al. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Dis Model Mech. 2016;9:941–52.CrossRefPubMedPubMedCentral
Metadaten
Titel
The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development
verfasst von
Mayumi Higashi
Kohei Sakai
Shigehisa Fumino
Shigeyoshi Aoi
Taizo Furukawa
Tatsuro Tajiri
Publikationsdatum
08.03.2019
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 9/2019
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-019-01790-0

Weitere Artikel der Ausgabe 9/2019

Surgery Today 9/2019 Zur Ausgabe

Original Article

A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient

Original Article

Development and validation of a nomogram predicting postoperative pneumonia after major abdominal surgery

Original Article

Preservation of physiological passage through the remnant stomach prevents postoperative malnutrition after proximal gastrectomy with double tract reconstruction

Original Article

Surgical outcome of pulmonary artery reconstruction using the expanded polytetrafluoroethylene patch in patients with lung cancer

Review Article

Short-term outcomes of a self-expandable metallic stent as a bridge to surgery vs. a transanal decompression tube for malignant large-bowel obstruction: a meta-analysis

Original Article

Surgical outcomes of pulmonary metastasis from hepatopancreatobiliary carcinomas: a comparison with pulmonary metastasis from colorectal carcinomas

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.